The stock of Delcath Systems, Inc. (NASDAQ:DCTH) is a huge mover today! About 103,880 shares traded hands. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 60.11% since April 18, 2016 and is downtrending. It has underperformed by 64.54% the S&P500.
The move comes after 6 months positive chart setup for the $4.50 million company. It was reported on Nov, 18 by Barchart.com. We have $3.99 PT which if reached, will make NASDAQ:DCTH worth $4.14M more.
According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”
Insitutional Activity: The institutional sentiment decreased to 0 in Q2 2016. Its down 1.13, from 1.13 in 2016Q1. The ratio dived, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
Blackrock Institutional Trust Na accumulated 531,871 shares or 0% of the stock. Renaissance Techs Ltd Liability Com accumulated 0% or 754,998 shares. Wells Fargo & Mn owns 157 shares or 0% of their US portfolio. Goldman Sachs Grp last reported 0% of its portfolio in the stock. Barclays Public Limited Liability Com accumulated 15 shares or 0% of the stock. Blackrock Fund accumulated 4,024 shares or 0% of the stock. Geode Management Ltd Liability Com owns 39,792 shares or 0% of their US portfolio. The Pennsylvania-based Vanguard Grp Inc has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Citadel Advsrs Ltd Liability, a Illinois-based fund reported 157,333 shares. Deutsche Bancorp Ag last reported 0% of its portfolio in the stock. Ladenburg Thalmann Financial Services accumulated 0% or 1,456 shares. Creative Planning has 0% invested in the company for 307 shares. Kcg Incorporated holds 0% or 12,403 shares in its portfolio. Susquehanna Group Limited Liability Partnership accumulated 39,047 shares or 0% of the stock. Royal Comml Bank Of Canada has 2,563 shares for 0% of their US portfolio.
More recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: Prnewswire.com which released: “Delcath Announces Third Quarter Financial Results” on November 11, 2016. Also Marketwatch.com published the news titled: “Delcath Systems Inc.” on December 22, 2009. Prnewswire.com‘s news article titled: “Delcath Issues Letter to Stockholders” with publication date: October 18, 2016 was also an interesting one.
DCTH Company Profile
Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.